Trials / Completed
CompletedNCT01217736
Direct Renin Inhibition and the Kidney
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Vitae Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The objective of the study is to determine the magnitude of the effect of direct renin inhibition by VTP-27999 on renal plasma flow and kidney function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aliskiren | single dose, tablet |
| DRUG | placebo | single dose, tablet |
| DRUG | VTP-27999 | single dose, tablet |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2010-10-08
- Last updated
- 2016-02-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01217736. Inclusion in this directory is not an endorsement.